经导管动脉化疗栓塞术联合^(125)I粒子植入治疗原发性肝癌的临床效果  

Clinical effect of transcatheter arterial chemoembolization combine with ~(125)I implantation in the treatment of primary liver cancer

作　　者：刘金文 李永强[2] LIU Jinwen;LI Yongqiang(Minimally Invasive Intervention Department of Guangzhou RoyalLee Tumor Hospital,Guangdong Guangzhou 510000,China;Oncology Department of Sun Yat sen University Cancer Center,Guangdong Guangzhou 510060,China)

机构地区：[1]广州皇家丽肿瘤医院微创介入科,广东广州510000 [2]中山大学肿瘤防治中心肿瘤内科,广东广州510060

出　　处：《临床普外科电子杂志》2023年第4期2-5,10,共5页Journal of General Surgery for Clinicians(Electronic Version)

摘　　要：目的 研究经导管动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)联合^(125)I粒子植入治疗原发性肝癌的效果。方法 选取广州皇家丽肿瘤医院2022年10月至2023年8月收治的70例原发性肝癌患者为研究对象,根据随机数字表法分为对照组(TACE治疗)和研究组(TACE联合^(125)I粒子植入治疗),各35例。比较两组患者的疾病缓解率、不良反应发生率、复发率,以及治疗前后的T细胞亚群(CD4+T细胞、CD8+T细胞)、炎症因子水平。结果 与对照组相比,研究组疾病缓解率更高(91.43%),复发率更低(5.71%),差异有显著性(P <0.05)。治疗前,两组T细胞亚群及炎症因子水平无显著差异(P> 0.05);治疗后,研究组CD4+T细胞、白介素-8水平低于对照组,CD8+T细胞、干扰素-γ水平高于对照组,差异有显著性(P <0.05)。两组不良反应发生率无显著差异(P> 0.05)。结论 TACE联合^(125)I粒子植入治疗原发性肝癌,疗效显著,且安全有效。Objective To study the effect of transcatheter arterial chemoembolization(TACE) combine with ~(125)I implantation in the treatment of primary liver cancer.Method A total of 70 patients with primary liver cancer admitted to Guangzhou RoyalLee Cancer Hospital from October 2022 to August 2023 were selected as the study subjects.They were divided into a control group(TACE treatment) and a study group(TACE combined with ~(125)I implantation treatment) based on a randomized number table method,with 35 patients in each group.The disease remission rate,adverse reaction rate,recurrence rate,and T cell subsets(CD4+,CD8+) and inflammatory factor levels before and after treatment were compared between the two groups.Result Compared with the control group,the remission rate of disease in the study group was higher(91.43%),the recurrence rate was lower(5.71%),the difference was statistically significant(P < 0.05).Before treatment,there was no significant difference in the levels of T cell subsets and inflammatory factors between the two groups(P > 0.05).After treatment,the levels of CD4+ and interleukin-8 in the study group were lower than those in the control group,while the levels of CD8+and interferon-γ were higher than those in the control group(P < 0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P > 0.05).Conclusion TACE combined with ~(125)I implantation in the treatment of primary liver cancer has significant efficacy,safety,and effectiveness.

关 键 词：经导管动脉化疗栓塞术 ^(125)I粒子 原发性肝癌 

分 类 号：R73[医药卫生—肿瘤]